US drugmaker starts phase 3 trial for COVID-19 antibody treatment
American pharmaceutical firm Eli Lilly and Company has announced the start of its phase 3 trial to study whether one of its experimental COVID-19 antibody treatments can prevent the virus infection in residents and staff at long-term care facilities. LY-CoV555, the lead antibody from Lilly’s collaboration with Canadian biotech AbCellera, is a neutralizing antibody against … Read more US drugmaker starts phase 3 trial for COVID-19 antibody treatment